Cargando…

Modeling and Simulation in Clinical Pharmacology and Dose Finding

The breakout session 2 of the European Medicines Agency/European Federation of Pharmaceutical Industries and Associations Modeling and Simulation (M&S) workshop focused on two topics: when and how M&S should be used and would be accepted by the authorities for the dose-regimen selection; and...

Descripción completa

Detalles Bibliográficos
Autores principales: Staab, A, Rook, E, Maliepaard, M, Aarons, L, Benson, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600758/
https://www.ncbi.nlm.nih.gov/pubmed/23835940
http://dx.doi.org/10.1038/psp.2013.5
_version_ 1782475674853834752
author Staab, A
Rook, E
Maliepaard, M
Aarons, L
Benson, C
author_facet Staab, A
Rook, E
Maliepaard, M
Aarons, L
Benson, C
author_sort Staab, A
collection PubMed
description The breakout session 2 of the European Medicines Agency/European Federation of Pharmaceutical Industries and Associations Modeling and Simulation (M&S) workshop focused on two topics: when and how M&S should be used and would be accepted by the authorities for the dose-regimen selection; and when and how M&S can be applied to register a dosing regimen without the need for a specific study. Each topic was introduced by an industry and regulatory perspective, followed by case examples for illustration (Table 1).
format Online
Article
Text
id pubmed-3600758
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36007582013-04-09 Modeling and Simulation in Clinical Pharmacology and Dose Finding Staab, A Rook, E Maliepaard, M Aarons, L Benson, C CPT Pharmacometrics Syst Pharmacol Perspective The breakout session 2 of the European Medicines Agency/European Federation of Pharmaceutical Industries and Associations Modeling and Simulation (M&S) workshop focused on two topics: when and how M&S should be used and would be accepted by the authorities for the dose-regimen selection; and when and how M&S can be applied to register a dosing regimen without the need for a specific study. Each topic was introduced by an industry and regulatory perspective, followed by case examples for illustration (Table 1). Nature Publishing Group 2013-02 2013-02-27 /pmc/articles/PMC3600758/ /pubmed/23835940 http://dx.doi.org/10.1038/psp.2013.5 Text en Copyright © 2013 American Society for Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ CPT: Pharmacometrics and Systems Pharmacology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Perspective
Staab, A
Rook, E
Maliepaard, M
Aarons, L
Benson, C
Modeling and Simulation in Clinical Pharmacology and Dose Finding
title Modeling and Simulation in Clinical Pharmacology and Dose Finding
title_full Modeling and Simulation in Clinical Pharmacology and Dose Finding
title_fullStr Modeling and Simulation in Clinical Pharmacology and Dose Finding
title_full_unstemmed Modeling and Simulation in Clinical Pharmacology and Dose Finding
title_short Modeling and Simulation in Clinical Pharmacology and Dose Finding
title_sort modeling and simulation in clinical pharmacology and dose finding
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600758/
https://www.ncbi.nlm.nih.gov/pubmed/23835940
http://dx.doi.org/10.1038/psp.2013.5
work_keys_str_mv AT staaba modelingandsimulationinclinicalpharmacologyanddosefinding
AT rooke modelingandsimulationinclinicalpharmacologyanddosefinding
AT maliepaardm modelingandsimulationinclinicalpharmacologyanddosefinding
AT aaronsl modelingandsimulationinclinicalpharmacologyanddosefinding
AT bensonc modelingandsimulationinclinicalpharmacologyanddosefinding